Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GALK1 | P51570 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687199 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL694944 | 0.79 | ILK (0.42) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL16480369 | 0.79 | MAPT (0.47) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL3634489 | 0.74 | HSD17B1 (0.63) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL3086399 | 0.73 | MAPT (0.61) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL7158014 | 0.73 | MAPT (0.64) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL6127587 | 0.73 | PDK1 (0.49) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL1748302 | 0.72 | CYP1A2 (0.58) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL31410 | 0.71 | HSD17B1 (0.73) | MAPTMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL2762136 | 0.70 | MAPT (0.67) | MAPTMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| EP-1542997-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, Inc. (CA) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004011460-A2 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | QLT, INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | REN, PGF, PKD1 | MAPT 4282/4885MEN1 4065/4885KMT2A 4078/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | MAPT 865/4885MEN1 4300/4885KMT2A 4397/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | MAPT 865/4885MEN1 4300/4885KMT2A 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.